Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
April 23, 2025 17:14 ET | Source: Supernus Pharmaceuticals, Inc. ROCKVILLE, Md.,…
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canadas Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYBs Acute Treatment of Migraine With or Without Aura in Cana
April 15, 2025 09:00 ET | Source: Scilex Holding Company ELYXYB® is…
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1×1 Meetings on Thursday, April 24, 2025
CARMEL, Ind., April 15, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or…
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th
March 25, 2025 16:05 ET | Source: Sight Sciences, Inc. MENLO PARK,…
reAlphas AiChat Unveils Next-Gen AI Agents
DUBLIN, Ohio, March 03, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (“reAlpha”…
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
February 28, 2025 17:00 ET | Source: Keros Therapeutics, Inc. LEXINGTON, Mass.,…
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe…
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
US Bankruptcy Court for the Southern District of Texas issued an order…
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great…
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
December 12, 2024 06:00 ET | Source: Keros Therapeutics, Inc. Keros will…